Inclusion Criteria:  Confirmed pathogenic germline mutation in either BRCA1 or BRCA2 Over the age of 18  Diagnosed with prostate cancer and at a time when staging imaging is clinically indicated; either:  At a new diagnosis Biochemically progressing patients who were treated radically with surgery or radiotherapy (more than 6 months ago) and are currently not receiving hormonal treatment or chemotherapy Patients on active surveillance with a PSA doubling time of 6 months or less  Exclusion Criteria:  Diagnosis of other malignancy (excluding basal cell cancer/squamous cell cancer of the skin) within five years of diagnosis Known metastatic prostate cancer, both local and distant Patients who have received any oncological treatment within the last six months Patients on any investigational drug treatment Patients on steroids Known history of inflammatory/infective diseases (e.g. sarcoidosis, tuberculosis, inflammatory bowel disease) Contraindications to having an MRI using the standard MRI checklist (e.g. pacemakers, aneurysm clips, claustrophobia)